Hydroxyethyl starch reduces high stretch ventilation-augmented lung injury via vascular endothelial growth factor

Transl Res. 2011 May;157(5):293-305. doi: 10.1016/j.trsl.2010.12.009. Epub 2011 Jan 22.

Abstract

Disruption of epithelial and endothelial barriers found in patients with acute lung injury often results in the need for the support of mechanical ventilation. High tidal volume (V(T)) mechanical ventilation can increase lung damage through lung inflammation, but the mechanisms are unclear. We hypothesized that a colloid supply with hydroxyethyl starch would decrease neutrophil infiltration, lung edema, and vascular endothelial growth factor (VEGF) production in mice exposed to high V(T) mechanical ventilation. Male C57BL/6 mice, weighing 20 g to 25 g, were exposed to high V(T) (30 mL/kg) mechanical ventilation with room air for 1 h to 5 h and infused with 15 mL/kg/h normal saline or hydroxyethyl starch intravenously at the beginning and every 30 min during ventilation. Evans blue dye, lung wet-to-dry weight ratio, histopathologic grading of lung tissue, myeloperoxidase, and inflammatory cytokine were measured to establish the extent of lung injury. Knockdown of VEGF by short interfering RNA (siRNA) was used to explore the role of VEGF. High V(T) ventilation induced the increases of microvascular permeability, neutrophil influx, expressions of VEGF mRNA and VEGF, production of VEGF protein, positive staining of VEGF in epithelium, and apoptotic epithelial cell death. Lung injury induced by high V(T) ventilation was attenuated with the supply of hydroxyethyl starch and pharmacologic inhibition of VEGF expression by siRNA. We conclude that hydroxyethyl starch reduces high V(T) mechanical ventilation-induced lung injury and neutrophil infiltration through an inhibition of VEGF expression.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Lung Injury / drug therapy
  • Acute Lung Injury / therapy*
  • Animals
  • Disease Models, Animal
  • Hydroxyethyl Starch Derivatives / therapeutic use*
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Plasma Substitutes / therapeutic use*
  • Respiration, Artificial
  • Vascular Endothelial Growth Factors / metabolism*
  • Ventilator-Induced Lung Injury / drug therapy
  • Ventilator-Induced Lung Injury / therapy*

Substances

  • Hydroxyethyl Starch Derivatives
  • Plasma Substitutes
  • Vascular Endothelial Growth Factors